| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study was to elucidate molecular procedures for oncogene fusion and carcinogenic pathways developing oncogene fusion positive lung cancer. The driver fusion cases showed a distinct profile with smaller numbers of non-synonymous mutations in cancer-related genes, indicating that lung adenocarvinomas (LADCs) with ALK, RET, and ROS1 fusions develop exclusively via their dependence on these oncogene fusions. The presence of such few alterations beyond the fusions supports the use of monotherapy with tyrosine kinase inhibitors targeting the fusion products in fusion-positive LADCs. Structural analysis of breakpoint junctions of ALK, RET, and ROS1 fusions demonstrated that oncogene fusion is produced by illegitimate repair of DSBs at unspecified sites in genomic regions of a few kb through DNA synthesis-dependent or -independent end-joining pathways.
|
